Chlamydia pneumoniae is a likely risk factor for ischemic stroke in young patients

Journal of Stroke and Cerebrovascular Diseases

Volumn 13, Issue 2, 2004, Pages 85-91

  Voorend, Manuela ^a,b   Faber, Carin G ^a   Van Der Ven, Andre J A M ^c   Kessels, Fons ^d   Bruggeman, Cathrien A ^b   Lodder, Jan ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

antibodies; cerebrovascular disorders; Chlamydia pneumoniae; young adults

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADULT; ANTIBODY TITER; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PERSISTENT INFECTION; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

EID: 3042804936     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2004.02.003     Document Type: Article

References (41)

1. Bogousslavsky J., Pierre P. Ischemic stroke in patients under age 45. Neurol Clin. 10:1992;113-124
2. Syrjanen J., Valtonen V.V., Iivanainen M., et al. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. BMJ. 296:1988;1156-1160
3. Grayston J.T., Campbell L.A., Kuo C.C., et al. A new respiratory tract pathogen Chlamydia pneumoniae strain TWAR. J Infect Dis. 161:1990;618-625
4. Grayston J.T. Infections caused by Chlamydia pneumoniae strain TWAR [see comments]. Clin Infect Dis. 15:1992;757-761
5. Karvonen M., Tuomilehto J., Pitkaniemi J., et al. Chlamydia pneumoniae IgG antibody prevalence in south-western and eastern Finland in 1982 and 1987. Int J Epidemiol. 23:1994;176-184
6. Saikku P., Leinonen M., Mattila K., et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 2:1988;983-986
7. Danesh J., Whincup P., Walker M., et al. Chlamydia pneumoniae IgG titres and coronary heart disease Prospective study and meta-analysis. BMJ. 321:2000;208-212
8. Kuo C.C., Shor A., Campbell L.A., et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 167:1993;841-849
9. Kuo C.C., Grayston J.T., Campbell L.A., et al. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A. 92:1995;6911-6914
10. Grayston J.T., Kuo C.C., Coulson A.S., et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery [see comments]. Circulation. 92:1995;3397-3400
11. Chiu B. Multiple infections in carotid atherosclerotic plaques. Am Heart J. 138:1999;S534-S536
12. Yamashita K., Ouchi K., Shirai M., et al. Distribution of Chlamydia pneumoniae infection in the athersclerotic carotid artery. Stroke. 29:1998;773-778
13. Virok D., Kis Z., Karai L., et al. Chlamydia pneumoniae in atherosclerotic middle cerebral artery. Stroke. 32:2001;1973-1976
14. Thomas M., Wong Y., Thomas D., et al. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. Circulation. 99:1999;2733-2736
15. Gaydos C.A., Summersgill J.T., Sahney N.N., et al. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun. 64:1996;1614-1620
16. Kaukoranta Tolvanen S.S., Teppo A.M., Laitinen K., et al. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog. 21:1996;215-221
17. Moazed T.C., Campbell L.A., Rosenfeld M.E., et al. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis. 180:1999;238-241
18. Muhlestein J.B., Anderson J.L., Hammond E.H., et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 97:1998;633-636
19. Wimmer M.L., Sandmann Strupp R., Saikku P., et al. Association of chlamydial infection with cerebrovascular disease. Stroke. 27:1996;2207-2210
20. Cook P.J., Honeybourne D., Lip G.Y.H., et al. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia The West Birmingham stroke project. Stroke. 29:1998;404-410
21. Elkind M.S., Lin I.F., Grayston J.T., et al. Chlamydia pneumoniae and the risk of first ischemic stroke The Northern Manhattan stroke study. Stroke. 31:2000;1521-1525
22. Fagerberg B., Gnarpe J., Gnarpe H., et al. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease A prospective study in middle-aged to elderly men with treated hypertension. Stroke. 30:1999;299-305
23. Schmidt C., Hulthe J., Wikstrand J., et al. Chlamydia pneumoniae seropositivity is associated with carotid artery intima-media thickness. Stroke. 31:2000;1526-1531
24. Markus H.S., Sitzer M., Carrington D., et al. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation. 100:1999;832-837
25. Melnick S.L., Shahar E., Folsom A.R., et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis risk in communities (ARIC) study investigators. Am J Med. 95:1993;499-504
26. Gordon D.L., Bendixen B.H., Adams H.P. Jr, et al. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke Implications for clinical trials. The TOAST investigators. Neurology. 43:1993;1021-1027
27. Dowell S.F., Peeling R.W., Boman J., et al. Standardizing Chlamydia pneumoniae assays Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis. 33:2001;492-503
28. Saikku P., Leinonen M., Tenkanen L., et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study [see comments]. Ann Intern Med. 116:1992;273-278
29. Glader C.A., Stegmayr B., Boman J., et al. Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in northern Sweden. Stroke. 30:1999;2013-2018
30. Toss H., Gnarpe J., Gnarpe H., et al. Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J. 19:1998;570-577
31. Hahn D.L., Golubjatnikov R. Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb. 12:1992;945-947
32. Cook P.J., Lip G.Y., Davies P., et al. Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension. 31:1998;589-594
33. Laurila A.L., Bloigu A., Nayha S., et al. Chlamydia pneumoniae antibodies associated with altered serum lipid profile. Int J Circumpolar Health. 57:(suppl):1998;329-332
34. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 325:1991;445-453
35. Ezzahiri R., Nelissen-Vrancken H., Kurvers H., et al. Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates formation of complex atherosclerotic lesions in Apo E3-Leiden mice. Cardiovasc Res. 56:2002;269-276
36. Maass M., Gieffers J., Krause E., et al. Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients. Med Microbiol Immunol (Berl). 187:1998;103-106
37. Gurfinkel E., Bozovich G., Beck E., et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study [see comments]. Eur Heart J. 20:1999;121-127
38. Anderson J.L., Muhlestein J.B., Carlquist J., et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The azithromycin in coronary artery disease Elimination of myocardial infection with Chlamydia (ACADEMIC) study [see comments]. Circulation. 99:1999;1540-1547
39. Gupta S., Leatham E.W., Carrington D., et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 96:1997;404-407
40. Dunne M.W. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction The WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial. J Infect Dis. 181:(suppl):2000;S572-S578
41. Jackson L.A. Description and status of the azithromycin and coronary events study (ACES). J Infect Dis. 181:(suppl):2000;S579-S581